Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - Impact of effector cells

Journal of Immunological Methods

Volumn 407, Issue , 2014, Pages 63-75

  Chung, Shan ^a   Lin, Yuwen L ^a   Reed, Chae ^a   Ng, Carl ^a   Cheng, Zhijie Jey ^b   Malavasi, Fabio ^c   Yang, Jihong ^a   Quarmby, Valerie ^a   Song, An ^a  

^a GENENTECH INC   (United States)

^b PROMEGA CORPORATION   (United States)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

ADCC assay; Afucosylated antibody; Antibody dependent cell mediated cytotoxicity; CD16a; Glycosylation; Monoclonal antibody

Indexed keywords

CD16A ANTIGEN; IMMUNOGLOBULIN G1 ANTIBODY; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ALLOTYPE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL ENGINEERING; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; EFFECTOR CELL; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADCC ASSAY; AFUCOSYLATED ANTIBODY; ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY; CD16A; GLYCOSYLATION; MONOCLONAL ANTIBODY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE; CYTOTOXICITY TESTS, IMMUNOLOGIC; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN ALLOTYPES; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; RECEPTORS, IGG; REPRODUCIBILITY OF RESULTS; TRANSGENES;

EID: 84901463516     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.03.021     Document Type: Article

References (41)

1. Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S., Weiner L.M. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J. Immunol. 2008, 180(9):6392.
2. Caligiuri M.A. Human natural killer cells. Blood 2008, 112(3):461.
3. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99(3):754.
4. Chavez-Galan L., Arenas-Del Angel M.C., Zenteno E., Chavez R., Lascurain R. Cell death mechanisms induced by cytotoxic lymphocytes. Cell. Mol. Immunol. 2009, 6(1):15.
5. Chung S., Quarmby V., Gao X., Yin Y., Lin L., Reed C., Fong C., Lau W., Qiu Z.J., Shen A., Vanderlaan M., Song A. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs 2012, 4(3):326.
6. Clemenceau B., Congy-Jolivet N., Gallot G., Vivien R., Gaschet J., Thibault G., Vie H. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood 2006, 107(12):4669.
7. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004, 64(13):4664.
8. Deaglio S., Zubiaur M., Gregorini A., Bottarel F., Ausiello C.M., Dianzani U., Sancho J., Malavasi F. Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. Blood 2002, 99(7):2490.
9. Derer S., Bauer P., Lohse S., Scheel A.H., Berger S., Kellner C., Peipp M., Valerius T. Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. J. Immunol. 2012, 189(11):5230.
10. Desjarlais J.R., Lazar G.A., Zhukovsky E.A., Chu S.Y. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov. Today 2007, 12(21-22):898.
11. Fanger M.W., Shen L., Graziano R.F., Ouvre P.M. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today 1989, 10(3):92-99.
12. Ferrara C., Stuart F., Sondermann P., Brünker P., Umaña P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 2006, 281(8):5032.
13. Gong J.H., Maki G., Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994, 8(4):652.
14. Griggs J., Zinkewich-Peotti K. The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br. J. Cancer 2009, 101(11):1807.
15. Hatjiharissi E., Xu L., Santos D.D., Hunter J.R., Ciccarelli B.T., Verselis S., Modica M., Cao Y., Manning R.J., Leleu X., Dimmock E.A., Kortsaris A., Mitsiades C., Anderson K.C., Fox E.A., Treon S.P. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 2007, 110(7):2561.
16. Jiang X.R., Song A., Bergelson S., Arroll T., Parekh B., May K., Chung S., Strouse R., Mire-Sluis A., Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 2011, 10(2):101.
17. Koene H.R., Kleijer M., Algra J., von dem Borne A.E., de Haas M. Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48 L/R/H phenotype. Blood 1997, 90(3):1109.
18. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., Dahiyat B.I. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(11):4005.
19. Lichtenfels R., Biddison W.E., Schulz H., Vogt A.B., Martin R. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J. Immunol. Methods 1994, 172(2):227.
20. Moretta A., Bottino C., Mingari M.C., Biassoni R., Moretta L. What is a natural killer cell?. Nat. Immunol. 2002, 3(1):6.
21. Nauseef W.M. Isolation of human neutrophils from venous blood. Methods Mol. Biol. 2007, 412:15.
22. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 2010, 9(10):767.
23. Neri S., Mariani E., Meneghetti A., Cattini L., Facchini A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin. Diagn. Lab. Immunol. 2001, 8(6):1131.
24. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8(1):34.
25. Okazaki A., Shoji-Hosaka E., Nakamura K., Wakitani M., Uchida K., Kakita S., Tsumoto K., Kumagai I., Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J. Mol. Biol. 2004, 336(5):1239.
26. Parekh B.S., Berger E., Sibley S., Cahya S., Xiao L., LaCerte M.A., Vaillancourt P., Wooden S., Gately D. Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs 2012, 4(3):310.
27. Peipp M., Lammerts van Bueren J.J., Schneider-Merck T., Bleeker W.W., Dechant M., Beyer T., Repp R., van Berkel P.H., Vink T., van de Winkel J.G., Parren P.W., Valerius T. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008, 112(6):2390.
28. Reichert J.M. Which are the antibodies to watch in 2013?. MAbs 2013, 5(1):1.
29. Robertson M.J., Cochran K.J., Cameron C., Le J.M., Tantravahi R., Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 1996, 24(3):406.
30. Rodríguez J., Zarate R., Bandres E., Boni V., Hernández A., Sola J.J., Honorato B., Bitarte N., Garcia-Foncillas J. Fc gamma receptor polymorphisms as predictive markers of cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur. J. Cancer 2012, 48(12):1774.
31. Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S., Zocher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol. Immunol. 2011, 48(12-13):1512.
32. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., Presta L.G. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 2001, 276(9):6591.
33. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277(30):6733.
34. Shuptrine C.W., Surana R., Weiner L.M. Monoclonal antibodies for the treatment of cancer. Semin. Cancer Biol. 2012, 22(1):3.
35. Tiroch K., Stockmeyer B., Frank C., Valerius T. Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. J. Immunol. 2002, 168(7):3275.
36. Umana P., Jean-Mairet J., Moudry R., Amstutz H., Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 1999, 17(2):176.
37. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003, 21(21):3940.
38. Würflein D., Dechant M., Stockmeyer B., Tutt A.L., Hu P., Repp R., Kalden J.R., van de Winkel J.G., Epstein A.L., Valerius T., Glennie M., Grammatzki M. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res. 1998, 58(14):3051.
39. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., Kusunoki M., Iida S., Nakano R., Wakitani M., Niwa R., Sakurada M., Uchida K., Shitara K., Satoh M. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 2004, 87(5):614.
40. Yodoi J., Teshigawara K., Nikaido T., Fukui K., Noma T., Honjo T., Takigawa M., Sasaki M., Minato N., Tsudo M., et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 1985, 134(3):1623.
41. Zalevsky J., Leung I.W., Karki S., Chu S.Y., Zhukovsky E.A., Desjarlais J.R., Carmichael D.F., Lawrence C.E. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009, 113(16):3735.